<?xml version='1.0' encoding='utf-8'?>
<document id="23001704"><sentence text="Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir."><entity charOffset="126-136" id="DDI-PubMed.23001704.s1.e0" text="boceprevir" /><entity charOffset="169-180" id="DDI-PubMed.23001704.s1.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.23001704.s1.e0" e2="DDI-PubMed.23001704.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23001704.s1.e0" e2="DDI-PubMed.23001704.s1.e1" /></sentence><sentence text="Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are likely to use both HIV and HCV treatment" /><sentence text=" Drug-drug interactions have been demonstrated between boceprevir, an HCV protease inhibitor, and frequently prescribed antiretroviral drugs, such as efavirenz and boosted HIV protease inhibitors"><entity charOffset="55-65" id="DDI-PubMed.23001704.s3.e0" text="boceprevir" /><entity charOffset="150-159" id="DDI-PubMed.23001704.s3.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23001704.s3.e0" e2="DDI-PubMed.23001704.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23001704.s3.e0" e2="DDI-PubMed.23001704.s3.e1" /></sentence><sentence text=" Concomitant administration of boceprevir with these drugs should be avoided"><entity charOffset="31-41" id="DDI-PubMed.23001704.s4.e0" text="boceprevir" /></sentence><sentence text=" This study was designed to investigate the absence of a drug-drug interaction between boceprevir and raltegravir, an HIV integrase inhibitor"><entity charOffset="87-97" id="DDI-PubMed.23001704.s5.e0" text="boceprevir" /><entity charOffset="102-113" id="DDI-PubMed.23001704.s5.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.23001704.s5.e0" e2="DDI-PubMed.23001704.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23001704.s5.e0" e2="DDI-PubMed.23001704.s5.e1" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, 2-period, crossover phase 1 trial in 24 healthy volunteers" /><sentence text=" All subjects were randomly assigned to receive boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400 mg on day 10 followed by a washout period and a single dose of raltegravir 400 mg on day 38, or the same medication in reverse order"><entity charOffset="48-58" id="DDI-PubMed.23001704.s8.e0" text="boceprevir" /></sentence><sentence text=" Blood samples for pharmacokinetics were collected and pharmacokinetic parameters were calculated" /><sentence text="" /><sentence text="The geometric mean (GM) of raltegravir area under the concentration-time curve (AUC)(0-12h) and maximum plasma concentration (C(max)) for raltegravir + boceprevir vs raltegravir alone were 4"><entity charOffset="27-38" id="DDI-PubMed.23001704.s11.e0" text="raltegravir" /></sentence><sentence text="27 (95% confidence interval [CI], 3" /><sentence text="22-5" /><sentence text="66) vs 4" /><sentence text="04 (95% CI, 3" /><sentence text="09-5" /><sentence text="28) mg * hour/L and 1" /><sentence text="06 (95% CI, " /><sentence text="76-1" /><sentence text="49) vs 0" /><sentence text="93 (95% CI, " /><sentence text="70-1" /><sentence text="23) mg/L, respectively" /><sentence text=" GM ratio estimates of raltegravir AUC(0-12h) and C(max) for raltegravir + boceprevir vs raltegravir alone were 1"><entity charOffset="23-45" id="DDI-PubMed.23001704.s24.e0" text="raltegravir AUC(0-12h)" /></sentence><sentence text="04 (90% CI, " /><sentence text="88-1" /><sentence text="22) and 1" /><sentence text="11 (90% CI, " /><sentence text="91-1" /><sentence text="36), respectively" /><sentence text=" The GM of boceprevir AUC(0-8h), C(max), and C(8h) were 5"><entity charOffset="11-31" id="DDI-PubMed.23001704.s31.e0" text="boceprevir AUC(0-8h)" /></sentence><sentence text="45 (95% CI, 5" /><sentence text="11-5" /><sentence text="81) mg * hour/L, 1" /><sentence text="88 (95% CI, 1" /><sentence text="72-2" /><sentence text="06) mg/L, and 0" /><sentence text="09 (95% CI, " /><sentence text="07-" /><sentence text="11) mg/L, respectively" /><sentence text=" These data are comparable to those from historical controls" /><sentence text="" /><sentence text="Due to the absence of a clinically significant drug interaction, raltegravir can be recommended for combined HIV/HCV treatment including boceprevir"><entity charOffset="65-76" id="DDI-PubMed.23001704.s43.e0" text="raltegravir" /><entity charOffset="137-147" id="DDI-PubMed.23001704.s43.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.23001704.s43.e0" e2="DDI-PubMed.23001704.s43.e0" /><pair ddi="false" e1="DDI-PubMed.23001704.s43.e0" e2="DDI-PubMed.23001704.s43.e1" /></sentence><sentence text="" /><sentence text="NCT01288417" /><sentence text="" /></document>